The Eurasian Modern Pollen Database (EMPD), version 2

The Eurasian (née European) Modern Pollen Database (EMPD) was established in 2013 to provide a public database of high-quality modern pollen surface samples to help support studies of past climate, land cover, and land use using fossil pollen. The EMPD is part of, and complementary to, the European Pollen Database (EPD) which contains data on fossil pollen found in Late Quaternary sedimentary archives throughout the Eurasian region. The EPD is in turn part of the rapidly growing Neotoma database, which is now the primary home for global palaeoecological data. This paper describes version 2 of the EMPD in which the number of samples held in the database has been increased by 60 % from 4826 to 8134. Much of the improvement in data coverage has come from northern Asia, and the database has consequently been renamed the Eurasian Modern Pollen Database to reflect this geographical enlargement. The EMPD can be viewed online using a dedicated map-based viewer at https://empd2.github.io and downloaded in a variety of file formats at https://doi.pangaea.de/10.1594/PANGAEA.909130 (Chevalier et al., 2019)Swiss National Science Foundation | Ref. 200021_16959

The Eurasian Modern Pollen Database (EMPD), version 2

The Eurasian (nee European) Modern Pollen Database (EMPD) was established in 2013 to provide a public database of high-quality modern pollen surface samples to help support studies of past climate, land cover, and land use using fossil pollen. The EMPD is part of, and complementary to, the European Pollen Database (EPD) which contains data on fossil pollen found in Late Quaternary sedimentary archives throughout the Eurasian region. The EPD is in turn part of the rapidly growing Neotoma database, which is now the primary home for global palaeoecological data. This paper describes version 2 of the EMPD in which the number of samples held in the database has been increased by 60% from 4826 to 8134. Much of the improvement in data coverage has come from northern Asia, and the database has consequently been renamed the Eurasian Modern Pollen Database to reflect this geographical enlargement. The EMPD can be viewed online using a dedicated map-based viewer at https://empd2.github.io and downloaded in a variety of file formats at https://doi.pangaea.de/10.1594/PANGAEA.909130 (Chevalier et al., 2019).Peer reviewe

Selection of DNA Aptamers for Breast Cancer

Текст статьи не публикуется в открытом доступе в соответствии с политикой журнала.A method of selection of DNA aptamers to breast tumor tissue based on the use of potoperative material has been developed. Breast cancer tissue were used as the positive target; the negative targets included benign tumor tissue, adjacent healthy tissue, breast tissues from mastopathy patients, and also tissue of other types of malignant tumors/ Tese DNA aptamers can be used for identification of protein markars, breast cancer diagnostics, and targeted delivery of anticancer drugs

Selection of DNA Aptamers for Breast Cancer

Текст статьи не публикуется в открытом доступе в соответствии с политикой журнала.A method of selection of DNA aptamers to breast tumor tissue based on the use of potoperative material has been developed. Breast cancer tissue were used as the positive target; the negative targets included benign tumor tissue, adjacent healthy tissue, breast tissues from mastopathy patients, and also tissue of other types of malignant tumors/ Tese DNA aptamers can be used for identification of protein markars, breast cancer diagnostics, and targeted delivery of anticancer drugs

In Vivo Cancer Cells Elimination Guided by Aptamer-Functionalized Gold-Coated Magnetic Nanoparticles and Controlled with Low Frequency Alternating Magnetic Field

Biomedical applications of magnetic nanoparticles in a magnetic field have exceeded many expectations in cancer therapy. Magnetic nanoparticles are effective heat mediators, drug nanocarriers, and contrast agents; various strategies have been suggested to selectively target tumor cancer cells but not healthy cells. Our study presents magnetodynamic nanotherapy utilizing DNA aptamer-functionalized 50 nm gold-coated magnetic nanoparticles exposed to a low frequency alternating magnetic field for precise elimination of tumor cells in vivo. The cell specific DNA aptamer AS-14 binds to fibronectin protein in Ehrlich carcinoma and delivers gold-coated magnetic nanoparticles to a mouse tumor. An alternating magnetic field of 50 Hz causesthe nanoparticles to oscillate and pull fibronectin and integrins on the surface of the cell membrane resulting in massive cell apoptosis followed by necrosis without heating the tumor, adjacent healthy cells and tissues. The aptamer-guided nanoparticles and the low frequency alternating magnetic field demonstrates a unique technology of a non-invasive nanoscalpel for precise cancer surgery at a single cell level

In Vivo Cancer Cells Elimination Guided by Aptamer-Functionalized Gold-Coated Magnetic Nanoparticles and Controlled with Low Frequency Alternating Magnetic Field

Biomedical applications of magnetic nanoparticles in a magnetic field have exceeded many expectations in cancer therapy. Magnetic nanoparticles are effective heat mediators, drug nanocarriers, and contrast agents; various strategies have been suggested to selectively target tumor cancer cells but not healthy cells. Our study presents magnetodynamic nanotherapy utilizing DNA aptamer-functionalized 50 nm gold-coated magnetic nanoparticles exposed to a low frequency alternating magnetic field for precise elimination of tumor cells in vivo. The cell specific DNA aptamer AS-14 binds to fibronectin protein in Ehrlich carcinoma and delivers gold-coated magnetic nanoparticles to a mouse tumor. An alternating magnetic field of 50 Hz causesthe nanoparticles to oscillate and pull fibronectin and integrins on the surface of the cell membrane resulting in massive cell apoptosis followed by necrosis without heating the tumor, adjacent healthy cells and tissues. The aptamer-guided nanoparticles and the low frequency alternating magnetic field demonstrates a unique technology of a non-invasive nanoscalpel for precise cancer surgery at a single cell level